四宮 義貴 (シノミヤ ヨシキ)

北海道大学病院 医療・ヘルスサイエンス研究開発機構特任助教
総合イノベーション創発機構ワクチン研究開発拠点特任助教

研究者基本情報

■ 学位
  • 博士(医学), 千葉大学
■ URL
researchmap URLホームページURL■ ID 各種
ORCID IDJ-Global ID■ 研究キーワード・分野
研究キーワード
  • 肺癌
  • 膵癌
  • 細胞形態学
研究分野
  • ライフサイエンス, ゲノム生物学
  • ライフサイエンス, 人体病理学

経歴

■ 経歴
経歴
  • 2024年04月 - 現在
    北海道大学, 大学病院, 特任助教
  • 2012年04月 - 2024年03月
    千葉大学医学部附属病院, 病理部, 日本国
学歴
  • 2020年04月 - 2024年03月, 千葉大学, 大学院医学薬学府, 先端医学薬学専攻(博士課程)
  • 2018年04月 - 2020年03月, 千葉大学, 大学院医学薬学府, 医科学専攻(修士課程)
  • 2008年04月 - 2012年03月, 北海道大学, 医学部保健学科
委員歴
  • 2026年04月 - 現在
    日本病理学会, ゲノム診療用病理組織検体取扱い規定策定WG
  • 2026年04月 - 現在
    日本病理学会, 固形癌HER2病理診断ガイダンス策定WG
  • 2026年04月 - 現在
    日本臨床衛生検査技師会, 医学検査査読委員

研究活動情報

■ 論文
  • Feasibility of routine clinical liquid-based cytology for lung cancer compact panel testing.
    Yoshiki Shinomiya; Kanako C Hatanaka; Asami Okumura; Ayae Nange; Mamiko Yamamoto; Manabu Azuma; Katsuji Marukawa; Yuko Ishida; Tomohiro Shimizu; Ryoko Watanabe; Yamato Hashimoto; Mitsuharu Abiko; Yoshiharu Sato; Jun Sakakibara-Konishi; Tatsuya Kato; Shinya Tanaka; Yutaka Hatanaka
    Cancer cytopathology, 134, 9, e70135, 2026年09月, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The Lung Cancer Compact Panel (cPANEL) is a recently approved highly sensitive multiplex gene panel in Japan that supports both DNA- and RNA-based next-generation sequencing. Although cytological specimens are acceptable for cPANEL, unfixed cell pellets or dedicated preservation tubes are typically recommended. However, evidence remains limited regarding whether residual liquid-based cytology (LBC) cell suspensions prepared for routine cytological diagnosis can be used directly for cPANEL testing without dedicated molecular preservation or additional preanalytical processing. In this study, we evaluated the feasibility of applying LBC specimens that are widely used in contemporary clinical practice to cPANEL. METHODS: We analyzed DNA and RNA quality in 69 clinical LBC specimens. Among these, 51 specimens containing non-small cell lung cancer cells with previously determined driver alteration status were subjected to cPANEL testing to evaluate assay concordance with clinical companion diagnostic results. RESULTS: DNA integrity was generally well preserved (DNA Integrity Number [DIN]: 6.2 ± 1.5). In contrast, RNA integrity showed greater variability (DV200: 16.4 ± 12.1%). ThinPrep-fixed specimens demonstrated lower DIN and DV200 values compared with CytoRich Red-fixed specimens. Although all samples successfully passed the DNA-based cPANEL assay, six cases (11.8%) failed the RNA-based assay, with RNA yield being a major contributing factor. Among the 46 evaluable specimens, concordance was 95.7% and sensitivity was 92.3%, or 88.9% including RNA module failures as cPANEL-negative. CONCLUSIONS: With appropriate fixative selection and adequate cellularity, cPANEL using clinical LBC specimens may serve as a practical diagnostic platform. We demonstrated that routine LBC specimens can be directly applied to cPANEL without special preanalytical processing.
  • Urinary miR-574-5p as a candidate biomarker for early-stage lung adenocarcinoma: an exploratory case-control study.
    Ryota Nagashima; Masato Aragaki; Kanako C Hatanaka; Yoshiki Shinomiya; Masaru Ushijima; Aki Fujiwara-Kuroda; Kazuto Ohtaka; Haruhiko Shiiya; Ryohei Chiba; Shinya Otsuka; Takumi Nakaya; Ritsu Omine; Tomoaki Kuji; Yutaka Hatanaka; Tatsuya Kato
    Translational lung cancer research, 15, 8, 244, 244, 2026年08月31日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Early detection of lung adenocarcinoma remains challenging despite advances in low-dose computed tomography (LDCT) screening. Urinary microRNAs (miRNAs) represent a non-invasive biomarker modality, but their clinical utility in early-stage disease remains unclear. This study aimed to identify urinary miRNA candidates associated with early-stage lung adenocarcinoma and to explore whether urinary miR-574-5p may provide complementary diagnostic information beyond established clinical risk factors. METHODS: We conducted an exploratory case-control study using urinary samples from the J-CAN cohort, a prospective biomarker study. Small RNA sequencing was performed to profile miRNAs. Candidate miRNAs were identified using edgeR and the Wilcoxon rank-sum test. Associations with lung cancer status were evaluated using multivariable Firth logistic regression adjusted for age, sex, smoking status, and urinary creatinine. Model performance was assessed using the area under the curve (AUC), and internal validation was performed using bootstrap resampling. RESULTS: A total of 77 participants (33 early-stage lung adenocarcinoma (stage 0-IA2) and 44 healthy controls) were included in the primary analysis. Among candidate miRNAs, miR-574-5p showed the most consistent overall signal. Urinary miR-574-5p expression was significantly decreased in patients with early-stage adenocarcinoma and remained independently associated with lung cancer status after adjustment [odds ratio (OR) 0.15, 95% confidence interval (CI): 0.02-0.53, P<0.001]. The baseline clinical model yielded an AUC of 0.961, which increased to 0.988 with the addition of miR-574-5p (ΔAUC =0.027), although this increase was not statistically significant. CONCLUSIONS: Urinary miR-574-5p was decreased in early-stage lung adenocarcinoma and was independently associated with disease status. Although its incremental diagnostic value was modest, urinary miR-574-5p may provide limited complementary information beyond established clinical risk factors. Further validation in independent and prospective cohorts is warranted.
  • Pathological and molecular characterization of a four-component combined small cell lung carcinoma: a case report.
    Yasuyuki Ikezawa; Yoshiki Shinomiya; Kanako C Hatanaka; Keishi Makita; Hiroki Nishimura; Toichiro Takagi; Yukiko Tabata; Mikio Watanabe; Satoshi Konno; Yutaka Hatanaka; Yasutaka Kawai
    Translational lung cancer research, 15, 5, 155, 155, 2026年05月31日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Combined small cell lung carcinoma (SCLC) is a rare entity and characterized by the coexistence of SCLC and non-small cell lung cancer (NSCLC) components. We report the first known case of combined SCLC containing three distinct NSCLC components: squamous cell carcinoma, pleomorphic carcinoma, and adenocarcinoma (AD). CASE DESCRIPTION: A 70-year-old man presented with right shoulder pain and underwent right upper lobectomy with en bloc chest wall resection and lymph node dissection. Histopathological examination of the resected specimen revealed four distinct histological components within the primary tumor. Comprehensive immunohistochemistry and molecular analyses, including RNA sequencing, were performed to characterize the tumor. A TP53 mutation was shared across all components, suggesting a common clonal origin, whereas additional genetic alterations were largely component specific. Clonal phylogenetic analysis indicated divergence from a common ancestral clone, supporting a structured multilineage evolutionary process. Transcriptomic profiling demonstrated lineage-associated expression patterns, and tumor microenvironment analysis revealed increased lymphocytic infiltration in the AD and pleomorphic carcinoma components, whereas proliferative signaling pathways were enriched in the SCLC component. CONCLUSIONS: These findings highlight pronounced intratumoral molecular and immunological heterogeneity. Although combined SCLC with three NSCLC components is exceedingly rare, this case provides novel insights into lineage diversification and the clonal evolution and biological diversity of combined SCLC. Further accumulation of similar cases with integrated molecular analyses is warranted to improve understanding of this rare subtype and inform future therapeutic strategies.
  • High CD73 Expression Is Associated with Poor Prognosis in Biliary Tract Cancer Through Reduced Stromal Tumor-Infiltrating Lymphocytes
    Shoya Shiratori; Kazumichi Kawakubo; Kanako C. Hatanaka; Takuma Kobayashi; Teppei Konishi; Yoshiki Shinomiya; Soichiro Oda; Shunichiro Nozawa; Hiroki Yonemura; Ryo Sugiura; Kazuaki Harada; Yoshitsugu Nakanishi; Takehiro Noji; Shinya Tanaka; Satoshi Hirano; Masaki Kuwatani; Yutaka Hatanaka; Naoya Sakamoto
    Cancers, 2026年03月18日, [査読有り], [国際誌]
    研究論文(学術雑誌)
  • Diagnostic Potential of Tn-MUC1 in Breast Cancer: A Novel Immunohistochemical Marker Reflecting Tumor Progression
    Ai Shimizu; Kanako C. Hatanaka; Ayae Nange; Asami Okumura; Masanori Takehashi; Yoshiki Shinomiya; Kentaro Naruchi; Masaharu Sato; Hiroshi Kase; Tomoko Mitsuhashi; Hiroko Yamashita; Yutaka Hatanaka; Yoshihiro Matsuno
    Laboratory Investigation, 2026年03月, [査読有り], [国際誌]
    研究論文(学術雑誌)
  • Feasibility study of photoimmunotherapy combination with ASP-1929 for vulvar, vaginal, and cervical cancer
    Ryutaro Yamamoto; Hiroshi Asano; Kanako C Hatanaka; Yoshiki Shinomiya; Hiroyuki Yamazaki; Hiroko Matsumiya; Michiko Nagamine; Yuko Sasajima; Yutaka Hatanaka; Hidemichi Watari
    Journal of Gynecologic Oncology, 2026年, [査読有り], [国際誌]
    研究論文(学術雑誌)
  • Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-Small Cell Lung Cancer.
    Daisuke Morinaga; Jun Sakakibara-Konishi; Ryohei Kamada; Masahiro Kashima; Kosuke Tsuji; Shotaro Ito; Megumi Furuta; Tetsuaki Shoji; Yuta Takashima; Hidenori Kitai; Yasuyuki Ikezawa; Hiroshi Taguchi; Tatsuya Kato; Yoshiki Shinomiya; Kanako C Hatanaka; Yutaka Hatanaka; Satoshi Konno
    Thoracic cancer, 16, 13, e70119, 2025年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: During the systemic treatment of patients with non-small cell lung cancer (NSCLC), oligoprogression (OP), a condition in which most lesions remain controlled while a few progress or develop, has recently attracted attention. Traditionally, systemic therapy is continued after disease progression; however, advancements in local ablation therapy (LAT), such as radiotherapy and surgery, have demonstrated clinical efficacy in patients with OP. The characteristics of patients who may benefit from LAT or their genetic background remain unclear. This study evaluated the frequency, clinicopathological characteristics, and efficacy of LAT in the treatment of OP. METHODS: A retrospective review was conducted of 510 patients with NSCLC who experienced disease progression after systemic therapy. RESULTS: Overall, 106/510 (23.6%) patients exhibited OP; among these, six patients who received only the best supportive care after OP were excluded. Systemic therapy alone was administered to 79 patients (79.0%), while 21 (21.0%) received LAT. Median local progression-free survival was numerically longer in the LAT group than in the systemic therapy-only group (8.3 and 6.7 months, respectively; p = 0.38). In addition, overall survival was also numerically longer in the LAT group than in the systemic therapy-only group (78.1 and 55.1 months, respectively; p = 0.57). Ribonucleic acid sequencing revealed an increase in extracellular matrix-related gene expression after OP, providing potential molecular insights. CONCLUSIONS: Although this study found no significant prognostic benefit of LAT in patients with OP, future research integrating clinical and molecular data may identify patients most likely to benefit from LAT.
  • Utility of a Novel High‐Sensitivity Multiplex Companion Diagnostic Test Using Formalin‐Fixed Paraffin‐Embedded Cell Block Materials of Non‐small Cell Lung Cancer
    Yoshiki Shinomiya; Yuko Ishida; Kanako C. Hatanaka; Mamiko Yamamoto; Ayae Nange; Asami Okumura; Yumi Wada; Mitsuharu Abiko; Tomohiro Shimizu; Ryoko Watanabe; Yamato Hashimoto; Yoshiharu Sato; Jun Sakakibara‐Konishi; Tatsuya Kato; Shinya Tanaka; Yutaka Hatanaka
    Cancer Medicine, 2025年07月, [査読有り], [筆頭著者], [国際誌]
    研究論文(学術雑誌)
  • Keratin 6A is expressed at the invasive front and enhances the progression of colorectal cancer.
    Sakurako Harada-Kagitani; Yusuke Kouchi; Yoshiki Shinomiya; Makoto Kodama; Gaku Ohira; Hisahiro Matsubara; Jun-Ichiro Ikeda; Takashi Kishimoto
    Laboratory investigation; a journal of technical methods and pathology, 102075, 102075, 2024年05月08日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Keratins are intermediate filament proteins in epithelial cells, and they are important for cytoskeletal organization. Keratin 6A (KRT6A), classified as a type II keratin, is normally expressed in stratified squamous epithelium and squamous cell carcinomas. Little is known about the expression and role of KRT6A in adenocarcinomas. We investigated the clinicopathological and molecular biological significance of KRT6A in colorectal adenocarcinoma. Immunostaining of our institution's colorectal adenocarcinoma cases demonstrated that KRT6A showed significantly stronger expression at the invasive front than the tumor center (p < 0.0001). The high-KRT6A-expression cases (n = 47) tended to have a high budding grade associated with significantly worse prognoses. A multivariate analysis revealed that the KRT6A expression status was an independent prognostic factor for overall survival (p = 0.0004), disease-specific survival (p = 0.0097) and progression-free survival (p = 0.0033). The correlation between KRT6A and patient prognoses was also validated in an external cohort from a published dataset. To determine the function of KRT6A in vitro, KRT6A was over-expressed in three colon cancer cell lines, DLD-1, SW620, and HCT 116. KRT6A overexpression increased migration and invasion in DLD-1, but did not in SW620 and HCT116. In three-dimensional sphere-forming culture, KRT6A expression enhanced the irregular protrusion around the spheroid in DLD-1. Our findings in the present study indicated that KRT6A expression is a valuable prognostic marker of colorectal cancer and KRT6A may be involved the molecular mechanism in the progression of invasive areas of colorectal cancer.
  • ECM1 and KRT6A are involved in tumor progression and chemoresistance in the effect of dexamethasone on pancreatic cancer.
    Yoshiki Shinomiya; Yusuke Kouchi; Sakurako Harada-Kagitani; Takayuki Ishige; Shigetsugu Takano; Masayuki Ohtsuka; Jun-Ichiro Ikeda; Takashi Kishimoto
    Cancer science, 2024年04月13日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), Pancreatic ductal adenocarcinoma (PDAC) has a very poor prognosis. Neoadjuvant chemotherapy is an effective PDAC treatment option, but chemotherapy causes unfavorable side effects. Glucocorticoids (e.g., dexamethasone [DEX]) are administered to reduce side effects of chemotherapy for solid tumors, including pancreatic cancer. Glucocorticoids have both beneficial and detrimental effects, however. We investigated the functional changes and gene-expression profile alterations induced by DEX in PDAC cells. PDAC cells were treated with DEX, and the cell proliferation, migration, invasion, and chemosensitivity to gemcitabine (GEM) were evaluated. The results demonstrated decreased cell proliferative capacity, increased cell migration and invasion, and decreased sensitivity to GEM. A comprehensive genetic analysis revealed marked increases in ECM1 and KRT6A in DEX-treated PDAC cells. We evaluated the effects of ECM1 and KRT6A expression by using PDAC cells transfected with those genes. Neither ECM1 nor KRT6A changed the cells' proliferation, but each enhanced cell migration and invasion. ECM1 decreased sensitivity to GEM. We also assessed the clinicopathological significance of the expressions of ECM1 and KRT6A in 130 cases of PDAC. An immunohistochemical analysis showed that KRT6A expression dominated the poorly differentiated areas. High expressions of these two proteins in PDAC were associated with a poorer prognosis. Our results thus demonstrated that DEX treatment changed PDAC cells' functions, resulting in decreased cell proliferation, increased cell migration and invasion, and decreased sensitivity to GEM. The molecular mechanisms of these changes involve ECM1 and KRT6A, whose expressions are induced by DEX.
  • Cystic primary squamous cell carcinoma of the thyroid.
    Sakurako Harada-Kagitani; Yusuke Kouchi; Yoshiki Shinomiya; Takuto Hiramoto; Tomoyuki Arai; Toyoyuki Hanazawa; Kiyotaka Onodera; Kaito Nakama; Takanori Aihara; Masayuki Ota; Jun-Ichiro Ikeda; Takashi Kishimoto
    Pathology international, 2024年03月28日, [査読有り], [国際誌]
    英語
  • Imprint Cytology of Tall Cell Carcinoma with Reversed Polarity of the Breast: A Case Report.
    Yoshiki Shinomiya; Yusuke Kouchi; Kiyotaka Onodera; Hiroto Yamamoto; Sakurako Harada-Kagitani; Junta Sakakibara; Takeshi Nagashima; Jun-Ichiro Ikeda; Takashi Kishimoto
    Acta cytologica, 68, 1, 73, 79, 2024年, [査読有り], [筆頭著者], [国際誌]
    英語, INTRODUCTION: Tall cell carcinoma with reversed polarity (TCCRP) is a rare histologic subtype of breast cancer that was newly categorized in 2020. TCCRP is a relatively novel tumor, and there are no detailed reports about its cellular morphology. We were able to obtain imprint cytological specimens from fresh TCCRP tissue, and we provide our detailed observations. CASE PRESENTATION: The patient was a 73-year-old Japanese female with a 15-mm mass in her right breast. After invasive breast carcinoma was diagnosed based on a core needle biopsy, a lumpectomy was performed. The pathological examination revealed TCCRP, and Sanger sequencing detected IDH2 p.R172M hotspot mutation, which is characteristic of TCCRP. Soon after the surgery, the lumpectomy specimen was sliced before fixation for use in a clinical trial, and imprint cytological materials were obtained from the tumor's cut surface. Cytologically, the tumor showed papillary-like cell clusters and isolated cells with moderate cellularity. Neoplastic cell aggregates and clusters with thick vascular cores as the axis or with delicate fibrovascular stroma were observed. Most of the neoplastic cells were cuboidal-to-columnar in shape, with mildly to moderately irregularly shaped blunt nuclei. Some intranuclear cytoplasmic inclusions and nuclear grooves were present, resembling the nuclear findings of papillary thyroid carcinoma. The most characteristic finding was the columnar cell clusters with apically located nuclei, giving the impression of reversed polarity. CONCLUSION: We described cytological findings in TCCRP, a newly classified rare mammary tumor. Most of the characteristic histologic findings were also observed in imprint cytological specimens. Further studies on practical specimens such as fine-needle aspiration are needed for clinical application.
  • Complex glandular pattern is an aggressive morphology that predicts poor prognosis of pancreatic ductal adenocarcinoma.
    Yusuke Kouchi; Shigetsugu Takano; Sakurako Harada-Kagitani; Yoshiki Shinomiya; Norikazu Yogi; Toshiya Sakamoto; Takashi Mishima; Kazunori Fugo; Michiyo Kambe; Yuichiro Nagai; Yukio Nakatani; Jun-Ichiro Ikeda; Masayuki Ohtsuka; Takashi Kishimoto
    Annals of diagnostic pathology, 64, 152110, 152110, 2023年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignant neoplasm with various morphologies. Recognition of histological patterns that can predict prognosis is important in pathological examination. Recently, the complex glandular pattern was defined as a morphology associating the poor prognosis in lung adenocarcinoma. We investigated the significance of the complex glandular pattern in PDAC by performing a retrospective analysis. Among 240 consecutive cases of conventional PDACs, 21 cases in which complex glandular pattern constituted >50 % of the total tumor volume (CG-PDACs) were identified. The prevalence of CG-PDAC was 8.8 % among all preoperative therapy-naïve and surgically resected conventional PDACs. Compared to the control PDACs (n = 95), the CG-PDACs were characterized by significantly higher prevalence of small- to medium-sized artery invasion (71.4 % vs. 14.7 %, p < 0.0001), intratumoral necrosis (59.1 % vs. 16.8 %, p < 0.0001), tumor budding (mean: 15.5 vs. 12.5 per 0.785 mm2, p = 0.04), significantly higher Ki67 proliferative index (mean: 75.0 % vs. 54.7 %, p < 0.0001), and the HNF1α-/KRT81+ (quasi-mesenchymal) immunophenotype (42.9 % vs. 19.0 %, p = 0.004). In Kaplan-Meier analyses, the CG-PDAC patients achieved significantly worse disease-free survival (DFS) and overall survival (OS) compared to the control PDAC patients; the respective median DFS and OS were 6.3 and 17.7 months for CG-PDACs, and 22.6 and 52.8 months for control PDACs. A multivariate Cox regression analysis showed that predominance of complex glandular pattern was an independent prognostic factor (hazard ratio: 2.95; 95 % confidence interval: 1.46-5.98; p = 0.003). Our results provide new insights into the complex glandular pattern in conventional PDACs as a novel and potentially useful prognostic factor.
  • Ovarian Malignant Mixed Germ Cell Tumor Composed Mainly of a Polyembryoma Pattern With Vasculogenic Mesenchymal Tumor Components.
    Yusuke Kouchi; Shugo Komatsu; Sakurako Harada; Yoshiki Shinomiya; Jun-Ichiro Ikeda; Takashi Kishimoto
    International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 42, 1, 78, 82, 2023年01月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Ovarian germ cell tumors composed of numerous well-formed embryonal bodies have been described as exhibiting a "polyembryoma pattern." In addition, some germ cell tumors are occasionally concomitant with neoplastic vascular proliferation. These include angiosarcomas and the recently reported mediastinal vasculogenic mesenchymal tumors. A 9-yr-old Japanese girl underwent surgery for a right ovarian tumor. Histologically, the polyembryoma pattern, nongestational choriocarcinoma, and vasculogenic lesions characterized by a neoplastic repetition of embryonic vasculogenesis have been intermingled. The polyembryoma pattern consisted of numerous complete and incomplete embryonal bodies and glandular structures resembling adult-type and fetal-type intestines. Vasculogenic lesions were composed of variously developed neoplastic vessels within the myxomatous stroma, which extended well beyond one low-power (40×) microscopic field. We concluded that the vasculogenic lesion in our case was the ovarian counterpart of the mediastinal vasculogenic mesenchymal tumor. After the surgery, the patient was administered adjuvant chemotherapy and was alive with no evidence of recurrence or other malignancy at 28 mo postsurgery.
  • Adenocarcinoma arising in an adrenohepatic fusion-related cyst.
    Yusuke Kouchi; Tsukasa Takayashiki; Sakurako Harada; Yoshiki Shinomiya; Katsuhiro Nasu; Jun-Ichiro Ikeda; Masayuki Ohtsuka; Takashi Kishimoto
    Pathology international, 72, 8, 426, 429, 2022年08月, [査読有り], [国際誌]
    英語
  • Solid serous neoplasm of the pancreas with locally aggressive behaviors.
    Yusuke Kouchi; Kazushi Yamashita; Sakurako Harada; Yoshiki Shinomiya; Takashi Mishima; Shigetsugu Takano; Keisuke Matsusaka; Katsuhiro Nasu; Jun-Ichiro Ikeda; Masayuki Ohtsuka; Takashi Kishimoto
    Pathology international, 71, 11, 795, 797, 2021年11月, [国際誌]
    英語
  • Rapid immunocytochemistry based on alternating current electric field using squash smear preparation of central nervous system tumors.
    Jun Moriya; Mishie Ann Tanino; Tomoko Takenami; Tomoko Endoh; Masana Urushido; Yasutaka Kato; Lei Wang; Taichi Kimura; Masumi Tsuda; Hiroshi Nishihara; Shinya Tanaka
    Brain tumor pathology, 33, 1, 13, 8, 2016年01月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The role of intraoperative pathological diagnosis for central nervous system (CNS) tumors is crucial for neurosurgery when determining the surgical procedure. Especially, treatment of carmustine (BCNU) wafers requires a conclusive diagnosis of high-grade glioma proven by intraoperative diagnosis. Recently, we demonstrated the usefulness of rapid immunohistochemistry (R-IHC) that facilitates antigen-antibody reaction under alternative current (AC) electric field in the intraoperative diagnosis of CNS tumors; however, a higher proportion of water and lipid in the brain parenchyma sometimes leads to freezing artifacts, resulting in poor quality of frozen sections. On the other hand, squash smear preparation of CNS tumors for cytology does not affect the frozen artifacts, and the importance of smear preparation is now being re-recognized as being better than that of the tissue sections. In this study, we established the rapid immunocytochemistry (R-ICC) protocol for squash smears of CNS tumors using AC electric field that takes only 22 min, and demonstrated its usefulness for semi-quantitative Ki-67/MIB-1 labeling index and CD 20 by R-ICC for intraoperative diagnosis. R-ICC by AC electric field may become a substantial tool for compensating R-IHC and will be applied for broad antibodies in the future.
  • Rapid immunohistochemistry based on alternating current electric field for intraoperative diagnosis of brain tumors.
    Mishie Tanino; Toshio Sasajima; Hiroshi Nanjo; Shiori Akesaka; Masami Kagaya; Taichi Kimura; Yusuke Ishida; Masaya Oda; Masataka Takahashi; Taku Sugawara; Toshiaki Yoshioka; Hiroshi Nishihara; Yoichi Akagami; Akiteru Goto; Yoshihiro Minamiya; Shinya Tanaka
    Brain tumor pathology, 32, 1, 12, 9, 2015年01月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Rapid immunohistochemistry (R-IHC) can contribute to the intraoperative diagnosis of central nervous system (CNS) tumors. We have recently developed a new IHC method based on an alternating current electric field to facilitate the antigen-antibody reaction. To ensure the requirement of R-IHC for intraoperative diagnosis, 183 cases of CNS tumors were reviewed regarding the accuracy rate of diagnosis without R-IHC. The diagnostic accuracy was 90.7 % (166/183 cases) [corrected] in which definitive diagnoses were not provided in 17 cases because of the failure of glioma grading and differential diagnosis of lymphoma and glioma. To establish the clinicopathological application, R-IHC for frozen specimens was compared with standard IHC for permanent specimens. 33 gliomas were analyzed, and the Ki-67/MIB-1 indices of frozen specimens by R-IHC were consistent with the grade and statistically correlated with those of permanent specimens. Thus, R-IHC provided supportive information to determine the grade of glioma. For discrimination between glioma and lymphoma, R-IHC was able to provide clear results of CD20 and Ki-67/MIB-1 in four frozen specimens of CNS lymphoma as well as standard IHC. We conclude that the R-IHC for frozen specimens can provide important information for intraoperative diagnosis of CNS tumors.
■ その他活動・業績
  • がん薬物治療選択に関わるバイオマーカー検査 いまとこれから(第10回) 肺癌分子標的治療と治療選択のための免疫組織化学検査のいまとこれから
    畑中 豊; 四宮 義貴; 畑中 佳奈子, 病理と臨床, 44, 9, 0924, 0927, 2026年09月
    (株)文光堂, 日本語
  • 大腸ステント留置期間に応じた機械的刺激が腫瘍微小環境に及ぼす経時的変化の網羅的解析
    浜田 卓巳; 今泉 健; 畑中 佳奈子; 四宮 義貴; 石黒 友唯; 下國 達志; 吉田 雅; 市川 伸樹; 畑中 豊; 武冨 紹信, 日本消化器外科学会総会, 81回, 1665, 1665, 2026年07月
    (一社)日本消化器外科学会, 日本語
  • AI-driven TILs spatial analysis to identify high-density hot spots as a superior prognostic marker in triple-negative breast cancer.
    Takuma Kobayashi; Kanako C. Hatanaka; Nobumoto Tomioka; Teppei Konishi; Yoshiki Shinomiya; Mateusz Grynkiewicz; Daisuke Komura; Shumpei Ishikawa; Kenichi Watanabe; Yutaka Hatanaka, JOURNAL OF CLINICAL ONCOLOGY, 44, 16_SUPPL, e12562, e12562, 2026年06月01日
    英語, 研究発表ペーパー・要旨(国際会議)
  • 甲状腺細胞診の補助検査 甲状腺癌における遺伝子検査の現状と展望
    畑中 佳奈子; 四宮 義貴; 畑中 豊, 日本臨床細胞学会雑誌, 65, Suppl.1, 149, 149, 2026年06月
    (公社)日本臨床細胞学会, 日本語
  • Identification of TROP2 as an adaptive resistance mechanism in KRAS G12C inhibition and its therapeutic targeting.
    Masahiro Kashima; Hidenori Kitai; Yukiko Yoshida; Yuriko Ishida; Yuma Sato; Daisuke Morinaga; Kosuke Tsuji; Shotaro Ito; Kanako C. Hatanaka; Takuma Kobayashi; Yoshiki Shinomiya; Teppei Konishi; Yutaka Hatanaka; Jun Sakakibara-Konishi; Satoshi Konno, CANCER RESEARCH, 86, 7, 2026年04月03日
    英語, 研究発表ペーパー・要旨(国際会議)
  • がん全ゲノム時代の病理学 がん全ゲノム解析における検体取扱いと臨床実装への病理学的観点からの課題
    畑中 佳奈子; 四宮 義貴; 畑中 豊, 日本病理学会会誌, 115, 1, 232, 232, 2026年03月
    (一社)日本病理学会, 日本語
  • 免疫組織化学検査全国調査から考える:病理の精度管理 免疫組織化学検査全国調査に関する報告
    畑中 豊; 四宮 義貴; 畑中 佳奈子; 孝橋 賢一, 日本病理学会会誌, 115, 1, 269, 269, 2026年03月
    (一社)日本病理学会, 日本語
  • 免疫組織化学検査全国調査から考える:病理の精度管理 臓器横断的観点からの免疫染色の精度管理
    孝橋 賢一; 四宮 義貴; 畑中 佳奈子; 畑中 豊, 日本病理学会会誌, 115, 1, 270, 270, 2026年03月
    (一社)日本病理学会, 日本語
  • 圧排性増殖を示した膀胱侵襲性血管粘液腫様病変の1例(Aggressive Angiomyxoma-like Lesion of the Bladder with Compressive Growth: A Case Report)
    中里 信一; 安達 正紘; 大澤 崇宏; 安部 崇重; 四宮 義貴; 畑中 佳奈子; 畑中 豊; 都築 豊徳; 田中 伸哉, 日本病理学会会誌, 115, 1, 369, 369, 2026年03月
    (一社)日本病理学会, 英語
  • 日本における非小細胞肺癌の最新ゲノムプロファイリング解析 C-CATデータを用いた実臨床解析(Updated genomic profiling of non-small cell lung cancer in Japan using the latest C-CAT data)
    四宮 義貴; 畑中 佳奈子; 杢 里花; 木下 一郎; 畑中 豊, 日本病理学会会誌, 115, 1, 378, 378, 2026年03月
    (一社)日本病理学会, 英語
  • ERBB2増幅大腸癌の臨床病理学的・ゲノム的特徴 CDK12共増幅および他の共変異の影響(Pathological and Genomic Insights into ERBB2-Amplified Colorectal Cancer with CDK12 Amplification)
    杢 里花; 有賀 伸; 大浦 果寿美; 四宮 義貴; 天野 虎次; 畑中 佳奈子; 畑中 豊; 田中 伸哉; 木下 一郎, 日本病理学会会誌, 115, 1, 405, 405, 2026年03月
    (一社)日本病理学会, 英語
  • 第一世代マルチCDxでドライバー変異陰性非小細胞肺癌を対象とした肺癌コンパクトパネル変異検出能の検証
    奥村 麻美; 畑中 佳奈子; 南家 綾江; 四宮 義貴; 佐藤 慶治; 榊原 純; 品川 尚文; 木下 一郎; 田中 伸哉; 畑中 豊, 日本病理学会会誌, 115, 1, 416, 416, 2026年03月
    (一社)日本病理学会, 日本語
  • 子宮頸部すりガラス細胞癌の分子免疫学的特徴解析(Molecular and Immunological Features of Cervical Glassy Cell Carcinoma)
    朝野 拓史; 畑中 佳奈子; 四宮 義貴; 村上 薫; 長谷部 理恵; 石塚 泰也; 村上 正晃; 畑中 豊; 渡利 英道, 日本病理学会会誌, 115, 1, 451, 451, 2026年03月
    (一社)日本病理学会, 英語
  • 広範なSMARCA4/BRG1欠損成分を伴うHPV関連子宮頸部腺癌の1例
    馬詰 知佐; 畑中 佳奈子; 加藤 万里絵; 篠原 敏也; 和田 真一郎; 四宮 義貴; 畑中 豊; 笹島 ゆう子; 太田 聡, 日本病理学会会誌, 115, 1, 517, 517, 2026年03月
    (一社)日本病理学会, 日本語
  • ドライバー遺伝子変異/転座陰性非小細胞肺癌におけるALK IHC追加検査の臨床有用性に関する検討
    嘉島相裕; 嘉島相裕; 畑中佳奈子; 畑中佳奈子; 四宮義貴; 太田聡; 佐々木高明; 谷野美智枝; 菊池創; 菊地慶介; 本庄統; 横尾慶紀; 品川尚文; 鈴木昭; 伊藤陽一; 木下一郎; 田中伸哉; 加藤達哉; 榊原純; 畑中豊, 日本呼吸器外科学会総会(Web), 43rd, 2026年
  • 気管支鏡による検体採取と治療の最前線 マルチ遺伝子検査に最適な検体とは
    畑中 豊; 四宮 義貴; 横内 浩; 佐々木 高明; 榊原 純; 品川 尚文; 畑中 佳奈子; 大泉 聡史, 肺癌, 65, 5, 346, 346, 2025年11月
    (NPO)日本肺癌学会, 日本語
  • がんゲノム診療における細胞検体の取扱い指針
    畑中 佳奈子; 四宮 義貴; 奥村 麻美; 森井 英一; 佐藤 之俊; 畑中 豊, 肺癌, 65, 5, 399, 399, 2025年11月
    (NPO)日本肺癌学会, 日本語
  • 全ゲノム解析の臨床実装に向けての現在地 がん全ゲノム解析における検体取扱いと実臨床検体のWGS応用
    四宮 義貴; 畑中 佳奈子; 畑中 豊, 日本臨床細胞学会雑誌, 64, Suppl.2, 455, 455, 2025年11月
    (公社)日本臨床細胞学会, 日本語
  • HR陽性HER2陰性乳癌の早期または晩期再発における網羅的遺伝子発現解析を用いた検討
    萩尾 加奈子; 畑中 佳奈子; 四宮 義貴; 奥村 麻美; 南家 綾江; 松島 由佳; 柏 和哉; 大東 元就; 木下 一郎; 高橋 將人; 畑中 豊, 日本乳癌学会総会プログラム抄録集, 33回, 432, 432, 2025年07月
    (一社)日本乳癌学会, 日本語
  • 4種類の組織型を含んだ混合型小細胞肺癌の1切除例
    高木 統一郎; 河井 康孝; 羅 昊; 木村 太俊; 小熊 昂; 牧田 啓史; 四宮 義貴; 畑中 佳奈子; 畑中 豊; 池澤 靖元, 肺癌, 65, 3, 208, 208, 2025年06月
    (NPO)日本肺癌学会, 日本語
  • 細胞検体を用いたゲノム診療の今後と課題 細胞検体を用いたゲノム診療の今後
    畑中 豊; 四宮 義貴; 畑中 佳奈子, 日本臨床細胞学会雑誌, 64, Suppl.1, 118, 118, 2025年06月
    (公社)日本臨床細胞学会, 日本語
  • 細胞検体を用いたゲノム診療の今後と課題 細胞検体を用いた全ゲノム解析に関するフィージビリティの検討
    四宮 義貴; 畑中 佳奈子; 奥村 麻美; 南家 綾江; 畑中 豊, 日本臨床細胞学会雑誌, 64, Suppl.1, 119, 119, 2025年06月
    (公社)日本臨床細胞学会, 日本語
  • がんゲノム医療の光と影 がんコンパニオン診断の現状 光と影
    畑中 豊; 四宮 義貴; 畑中 佳奈子, 日本臨床細胞学会雑誌, 64, Suppl.1, 173, 173, 2025年06月
    (公社)日本臨床細胞学会, 日本語
  • AI-powered quantification of tumor-infiltrating lymphocytes from H&E stained images in ovarian cancer and its association with PARP inhibitor therapy outcomes.
    Hiroshi Asano; Kanako C. Hatanaka; Takuma Kobayashi; Teppei Konishi; Hiroyuki Kurosu; Hiroko Matsumiya; Yoshiki Shinomiya; Ryo Matoba; Daisuke Komura; Shumpei Ishikawa; Shinya Tanaka; Hidemichi Watari; Yutaka Hatanaka, Journal of Clinical Oncology, 43, 16_suppl, 5575, 5575, 2025年06月
    英語, 研究発表ペーパー・要旨(国際会議)
  • IDH2 p.R172M変異を伴うtall cell carcinoma with reversed polarityの1例
    山田 蓮翔; 高地 祐輔; 四宮 義貴; 鍵谷 桜子; 山本 寛人; 榊原 淳太; 長嶋 健; 池田 純一郎; 岸本 充, 日本病理学会会誌, 114, 1, 448, 448, 2025年03月
    (一社)日本病理学会, 日本語
  • マルチ遺伝子検査に最適な検体とは
    畑中豊; 四宮義貴; 横内浩; 佐々木高明; 榊原純; 品川尚文; 品川尚文; 畑中佳奈子; 大泉聡史, 日本肺癌学会学術集会号(CD-ROM), 66th, 2025年
  • デキサメタゾンは,ECM1とKRT6Aの発現誘導により膵臓がんの腫瘍進行と化学療法耐性を引き起こす
    四宮義貴; 高地祐輔; 鍵谷桜子; 石毛崇之; 石毛崇之; 畑中佳奈子; 畑中豊; 高野重紹; 大塚将之; 池田純一郎; 池田純一郎; 岸本充, 日本癌学会学術総会抄録集(Web), 84th, 2025年
  • ASP-1929を用いた光免疫療法の婦人科悪性腫瘍における適用可能性の検討
    山本竜太郎; 畑中佳奈子; 朝野拓史; 四宮義貴; 渡利英道; 畑中豊, 日本がん分子標的治療学会学術集会プログラム・抄録集, 29th, 2025年
  • 細胞検体を用いたゲノム診療の今後
    畑中豊; 四宮義貴; 畑中佳奈子, 日本臨床細胞学会雑誌(Web), 64, 2025年
  • 甲状腺癌におけるドライバー変異の免疫組織化学的検出に関する検討
    南家綾江; 畑中佳奈子; 山本万美子; 奥村麻美; 四宮義貴; 田中伸哉; 廣川満良; 加藤良平; 畑中豊, 日本病理学会会誌, 114, 1, 2025年
  • 多機関共同研究による甲状腺乳頭癌の分子病理学的解析
    畑中佳奈子; 山本万美子; 南家綾江; 奥村麻美; 樋口観世子; 天野高志; 四宮義貴; 廣川満良; 加藤良平; 畑中豊, 日本病理学会会誌, 114, 1, 2025年
  • 連続迅速自動固定包埋装置により処理された組織検体の核酸品質に関する検討
    四宮義貴; 村山理子; 田中佑実; 下道真由美; 南家綾江; 石田裕子; 若林健人; 外丸詩野; 畑中豊; 畑中佳奈子, 日本病理学会会誌, 114, 1, 2025年
  • 非小細胞肺癌におけるoligoprogressionの頻度および局所治療が予後に与える影響についての検討
    森永大亮; 榊原純; 北井秀典; 池澤靖元; 加藤達哉; 四宮義貴; 畑中佳奈子; 畑中豊; 田口大志; 今野哲, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 38th, 2025年
  • LBCとゲノム[ゲノム診療時代における細胞診のあり方検討WG] 呼吸器領域の細胞検体を用いたゲノム診断の課題と今後の展望
    畑中 佳奈子; 四宮 義貴; 奥村 麻美; 南家 綾江; 田中 佑実; 山本 万美子; 東 学; 石田 裕子; 丸川 活司; 畑中 豊, 日本臨床細胞学会雑誌, 63, Suppl.2, 494, 494, 2024年10月
    (公社)日本臨床細胞学会, 日本語
  • 原発不明癌の細胞診 原発不明癌におけるゲノム検査の変遷と今後
    四宮 義貴; 畑中 佳奈子; 畑中 豊, 日本臨床細胞学会雑誌, 63, Suppl.2, 508, 508, 2024年10月
    (公社)日本臨床細胞学会, 日本語
  • 千葉県における鍍銀染色精度管理報告 アルコール分別方法の差による鍍銀染色への影響についての検討
    山崎 利城; 四宮 義貴; 齋藤 夏海; 中村 信之; 田口 晴丈; 安達 純世; 鈴木 学; 諏訪 朋子, 日本医学検査学会抄録集, 73回, 389, 389, 2024年05月
    (一社)日本臨床衛生検査技師会, 日本語
  • 核酸品質の視点からみた細胞診検体取扱い 呼吸器領域における細胞検体の取扱いと核酸品質
    四宮 義貴; 畑中 佳奈子; 奥村 麻美; 南家 綾江; 田中 佑実; 山本 万美子; 東 学; 石田 裕子; 畑中 豊, 日本臨床細胞学会雑誌, 63, Suppl.1, 138, 138, 2024年05月
    (公社)日本臨床細胞学会, 日本語
  • 浸潤性膵管癌における複雑腺管(篩状)パターンは高悪性度な組織形態で予後不良な臨床経過を反映する
    高地 祐輔; 鍵谷 桜子; 四宮 義貴; 富居 一範; 神戸 美千代; 永井 雄一郎; 中谷 行雄; 池田 純一郎; 大塚 将之; 岸本 充, 日本病理学会会誌, 113, 1, 318, 318, 2024年02月
    (一社)日本病理学会, 日本語
  • 60代後半で急性白血病に伴い死亡したウェルナー症候群の一剖検例
    鍵谷 桜子; 高地 祐輔; 四宮 義貴; 渡邉 涼香; 山口 彩乃; 前澤 喜朗; 池田 純一郎, 日本病理学会会誌, 113, 1, 344, 344, 2024年02月
    (一社)日本病理学会, 日本語
  • 気管支組織を模した胃ポリープを伴う喉頭気管食道裂(LTEC)の1例
    中本 真緒; 鍵谷 桜子; 高地 祐輔; 四宮 義貴; 中谷 恵理香; 照井 慶太; 菱木 知郎; 池田 純一郎; 岸本 充, 日本病理学会会誌, 113, 1, 481, 481, 2024年02月
    (一社)日本病理学会, 日本語
  • 星芽腫の細胞像と上衣腫との鑑別点
    大前龍生; 小野寺清隆; 鈴木学; 曽川紀子; 中千裕; 岩井優; 四宮義貴; 高橋大樹; 太田昌幸; 太田昌幸; 池田純一郎; 池田純一郎; 池田純一郎, 日本臨床細胞学会雑誌(Web), 62, 2023年
  • Isolated high-grade pancreatic intraepithelial neoplasia(PanIN)の2症例
    高地祐輔; 鍵谷桜子; 鍵谷桜子; 四宮義貴; 四宮義貴; 江藤亮大郎; 三島敬; 那須克宏; 池田純一郎; 池田純一郎; 大塚将之; 岸本充, 日本病理学会会誌, 112, 1, 2023年
  • 膵管癌におけるデキサメタゾンによるKRT6A発現誘導と遊走能亢進
    四宮義貴; 鍵谷桜子; 高地祐輔; 石毛崇之, 日本病理学会会誌, 112, 1, 2023年
  • 嚢胞性発育を呈した甲状腺原発扁平上皮癌の一例
    鍵谷桜子; 高地祐輔; 高地祐輔; 四宮義貴; 四宮義貴; 平本琢人; 花澤豊行; 岸本充; 池田純一郎, 日本病理学会会誌, 112, 1, 2023年
  • 甲状腺髄様癌の一例
    大前龍生; 鈴木学; 曽川紀子; 中千裕; 岩井優; 四宮義貴; 高橋大樹; 小野寺清隆, 千臨技会誌, 141, 2022年
  • デキサメタゾンによるヒト膵腺癌細胞における粘液形質変化
    四宮義貴; 原田桜子; 高地祐輔; 池田純一郎; 岸本充, 日本病理学会会誌, 111, 1, 2022年
  • 母児間輸血症候群による胎児貧血から心不全に至った一剖検例
    原田桜子; 原田桜子; 高地祐輔; 高地祐輔; 四宮義貴; 四宮義貴; 遠藤真美子; 佐藤美香; 池田純一郎; 岸本充, 日本病理学会会誌, 111, 1, 2022年
  • Adrenohepatic fusion-related cyst(AHF-RC)に生じた腺癌の1例
    高地祐輔; 高地祐輔; 原田桜子; 原田桜子; 四宮義貴; 四宮義貴; 高屋敷吏; 那須克宏; 池田純一郎; 池田純一郎; 大塚将之; 岸本充, 日本病理学会会誌, 111, 1, 2022年
  • 千葉県における病理検査精度管理の現状と試み
    四宮義貴; 東和彦; 豊永安洋; 草野広行; 坪内優子; 櫻井真琴, 日本医学検査学会(Web), 66th, 2017年
  • PD-L1を用いた免疫組織化学染色におけるセルブロックの有用性について
    四宮義貴; 小野寺清隆; 三枝文恵; 岩井優; 高橋大樹; 相田真莉菜; 大木昌二, 日本医学検査学会(Web), 66th, 2017年
  • 肺転移をきたした膵solid-pseudopapillary neoplasmの一例
    四宮義貴; 小野寺清隆; 曽川紀子; 鈴木学; 中千裕; 岩井優; 大木昌二; 米盛葉子; 米盛葉子; 米盛葉子; 太田聡; 太田聡; 矢澤卓也; 矢澤卓也; 矢澤卓也; 宮崎勝; 吉野一郎; 中谷行雄; 中谷行雄; 中谷行雄, 日本臨床細胞学会雑誌(Web), 54, 2015年
  • 免疫組織化学染色における非接触電界撹拌装置の使用経験
    小木義貴; 小野寺清隆; 鈴木学; 曽川紀子; 米川球恵; 山田千裕; 岩井優; 大木昌二, 千臨技会誌, 120, 2014年
  • クリューバー・バレラ染色におけるクレシル紫液の検討
    小木義貴; 小野寺清隆; 鈴木学; 米川球恵; 山田千裕; 岩井優; 大木昌二, 千臨技会誌, 117, 2013年
■ 所属学協会
  • 日本肺癌学会
  • 日本癌学会
  • 日本病理学会
  • 日本臨床細胞学会
■ 共同研究・競争的資金等の研究課題